Peterlin, P., Heiblig, M., Morisset, S., Bertoli, S., Sebert, M., Cluzeau, T., Orvain, C., Dumas, P., Musiu, P., Garciaz, S., Desbrosses, Y., Requena, G. A., Birsen, R., Turlure, P., Simand, C., Contejean, A., Salanoubat, C., Carpentier, B., Marcais, A., Lambert, J., Lebon, D., Cabrera, Q., Bonnet, S., Laribi, K., Banos, A., Daniel, A., Ochmann, M., Pautas, C., Papoular, B., Frayfer, J., Pica, G. M., HIEULLE, J., Vallet, N., Mineur, A., Pigneux, A., Récher, C., Botton, S. D. (2025). Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo. Blood. https://doi.org/10.1182/blood-2025-1658